Zhao Junjie, Xu Lixia, Dong Zihui, Zhang Yize, Cao Junhua, Yao Jie, Xing Jiyuan
Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Cell Dev Biol. 2022 Feb 3;10:832388. doi: 10.3389/fcell.2022.832388. eCollection 2022.
Cancer is one of the most prevalent and deadliest diseases globally, with an increasing morbidity of approximately 14 million new cancer cases per year. Identifying novel diagnostic and prognostic biomarkers for cancers is important for developing cancer therapeutic strategies and lowering mortality rates. Long noncoding RNAs (lncRNAs) represent a group of noncoding RNAs of more than 200 nucleotides that have been shown to participate in the development of human cancers. The novel lncRNA DUXAP10 was newly reported to be abnormally overexpressed in several cancers and positively correlated with poor clinical characteristics of cancer patients. Multiple studies have found that DUXAP10 widely regulates vital biological functions related to the development and progression of cancers, including cell proliferation, apoptosis, invasion, migration, and stemness, through different molecular mechanisms. The aim of this review was to recapitulate current findings regarding the roles of DUXAP10 in cancers and evaluate the potential of DUXAP10 as a novel biomarker for cancer diagnosis, treatment, and prognostic assessment.
癌症是全球最普遍且最致命的疾病之一，每年新增癌症病例约1400万，发病率呈上升趋势。识别癌症新的诊断和预后生物标志物对于制定癌症治疗策略和降低死亡率至关重要。长链非编码RNA（lncRNA）是一类长度超过200个核苷酸的非编码RNA，已被证明参与人类癌症的发生发展。新报道的lncRNA DUXAP10在多种癌症中异常高表达，且与癌症患者的不良临床特征呈正相关。多项研究发现，DUXAP10通过不同分子机制广泛调控与癌症发生发展相关的重要生物学功能，包括细胞增殖、凋亡、侵袭、迁移和干性。本综述的目的是总结目前关于DUXAP10在癌症中作用的研究结果，并评估DUXAP10作为癌症诊断、治疗和预后评估新生物标志物的潜力。
